EA201391714A1 - Применение иммуноконъюгированного с майтанзиноидом антитела против cd19 для лечения симптомов b-клеточных злокачественных новообразований - Google Patents

Применение иммуноконъюгированного с майтанзиноидом антитела против cd19 для лечения симптомов b-клеточных злокачественных новообразований

Info

Publication number
EA201391714A1
EA201391714A1 EA201391714A EA201391714A EA201391714A1 EA 201391714 A1 EA201391714 A1 EA 201391714A1 EA 201391714 A EA201391714 A EA 201391714A EA 201391714 A EA201391714 A EA 201391714A EA 201391714 A1 EA201391714 A1 EA 201391714A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunoconjuged
symptoms
treatment
application
antibody against
Prior art date
Application number
EA201391714A
Other languages
English (en)
Other versions
EA028574B1 (ru
Inventor
Родика Морарию
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085972&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201391714(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи filed Critical Санофи
Publication of EA201391714A1 publication Critical patent/EA201391714A1/ru
Publication of EA028574B1 publication Critical patent/EA028574B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Иммуноконъюгат майтанзиноида против CD19 используют для лечения симптома В-клеточных злокачественных новообразований, в частности неходжкинской лимфомы.
EA201391714A 2011-05-17 2012-05-16 Способ лечения b-клеточных злокачественных новообразований, экспрессирующих cd19 EA028574B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11290232.5 2011-05-17
EP11290232A EP2524929A1 (en) 2011-05-17 2011-05-17 Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
PCT/EP2012/059141 WO2012156455A1 (en) 2011-05-17 2012-05-16 Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms

Publications (2)

Publication Number Publication Date
EA201391714A1 true EA201391714A1 (ru) 2014-03-31
EA028574B1 EA028574B1 (ru) 2017-12-29

Family

ID=46085972

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391714A EA028574B1 (ru) 2011-05-17 2012-05-16 Способ лечения b-клеточных злокачественных новообразований, экспрессирующих cd19

Country Status (30)

Country Link
US (2) US9555126B2 (ru)
EP (2) EP2524929A1 (ru)
JP (4) JP6050328B2 (ru)
KR (1) KR20140043388A (ru)
CN (2) CN103547596A (ru)
AR (1) AR086412A1 (ru)
AU (3) AU2012258254B2 (ru)
BR (1) BR112013029330A8 (ru)
CA (1) CA2835738A1 (ru)
CL (1) CL2013003272A1 (ru)
CO (1) CO6821893A2 (ru)
CR (1) CR20130593A (ru)
DO (1) DOP2013000260A (ru)
EA (1) EA028574B1 (ru)
EC (1) ECSP13013084A (ru)
GT (1) GT201300276A (ru)
IL (3) IL229380B (ru)
MA (1) MA35180B1 (ru)
MX (1) MX347019B (ru)
MY (1) MY163736A (ru)
NI (1) NI201300119A (ru)
PE (1) PE20141018A1 (ru)
PH (1) PH12017501368A1 (ru)
SG (2) SG194894A1 (ru)
TN (1) TN2013000468A1 (ru)
TW (3) TW201726167A (ru)
UA (1) UA114401C2 (ru)
UY (1) UY34077A (ru)
WO (1) WO2012156455A1 (ru)
ZA (1) ZA201309400B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2777714A1 (en) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
WO2015031815A2 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
CN105837689B (zh) * 2015-01-13 2020-06-19 博生吉安科细胞技术有限公司 抗cd19单克隆抗体及其制备方法
WO2016180941A1 (en) * 2015-05-13 2016-11-17 Sanofi Liquid compositions for anti-cd19 antibody-drug conjugates
CN107660151B (zh) 2015-05-26 2022-03-11 莫佛塞斯公司 抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途
MX2018002241A (es) 2015-08-21 2018-03-23 Morphosys Ag Combinaciones y sus usos.
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
EP4335851A3 (en) 2015-11-25 2024-06-05 ImmunoGen, Inc. Pharmaceutical formulations and methods of use thereof
CN109313194B (zh) 2016-05-30 2022-11-04 莫佛塞斯公司 预测cd19抗体治疗在患者中的治疗益处的方法
PT3475303T (pt) 2016-06-27 2021-06-25 Morphosys Ag Formulações de anticorpos anti-cd19
RS62036B1 (sr) 2016-10-28 2021-07-30 Morphosys Ag Kombinacija anti cd19 antitela sa bcl-2 inhibitorom i njihova upotreba
WO2018183494A1 (en) * 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
KR20190137151A (ko) * 2017-04-20 2019-12-10 에이디씨 테라퓨틱스 에스에이 병용 요법
WO2018229222A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
EP3684820A4 (en) * 2017-09-21 2021-05-26 Wuxi Biologics (Cayman) Inc. NOVEL ANTI-CD19 ANTIBODIES
WO2019140141A1 (en) 2018-01-12 2019-07-18 Immunogen, Inc. Methods for antibody drug conjugation, purification, and formulation
PT3958977T (pt) 2019-04-26 2023-12-15 Immunogen Inc Derivados de camptotecina
CN114072424A (zh) 2019-05-03 2022-02-18 莫佛塞斯公司 具有有限数量的nk细胞的患者中的抗cd19疗法
CN114599392A (zh) * 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
MX2022005031A (es) 2019-10-31 2022-07-27 Morphosys Ag Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas.
MX2022005033A (es) 2019-10-31 2022-09-09 Morphosys Ag Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta.
CN111303287B (zh) * 2019-12-05 2022-05-20 常州费洛斯药业科技有限公司 一种anti-CD19的全人源抗体或抗体片段及其嵌合抗原受体和应用
EP4168449A1 (en) 2020-06-22 2023-04-26 MorphoSys AG Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
EP4225794A1 (en) 2020-10-06 2023-08-16 Xencor, Inc. Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
WO2022117799A2 (en) 2020-12-04 2022-06-09 Morphosys Ag Anti-cd19 combination therapy
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
CN1956722A (zh) * 2003-05-20 2007-05-02 伊缪诺金公司 含有新的美登素类的改进的细胞毒剂
ATE551071T1 (de) * 2006-09-08 2012-04-15 Medimmune Llc Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
BRPI1008749B8 (pt) * 2009-02-05 2021-05-25 Immunogen Inc compostos derivados de benzodiazepina, seus conjugados, composição farmacêutica, seu uso e seus processos de preparação
SG10201401976YA (en) * 2009-05-06 2014-10-30 Biotest Ag Uses of immunoconjugates targeting cd138
MX2012004406A (es) * 2009-10-21 2012-05-08 Immunogen Inc Nuevo regimen de dosificacion y metodo de tratamiento.
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2550975A1 (en) * 2011-07-29 2013-01-30 Sanofi Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab

Also Published As

Publication number Publication date
IL229380A0 (en) 2014-01-30
PE20141018A1 (es) 2014-08-27
ECSP13013084A (es) 2014-01-31
TN2013000468A1 (en) 2015-03-30
AU2016206317A1 (en) 2016-08-11
SG10201609729VA (en) 2016-12-29
IL257475A (en) 2018-06-28
MX347019B (es) 2017-04-07
UA114401C2 (uk) 2017-06-12
BR112013029330A8 (pt) 2018-01-30
CR20130593A (es) 2014-01-09
AU2012258254A1 (en) 2013-05-02
MY163736A (en) 2017-10-31
DOP2013000260A (es) 2014-01-31
GT201300276A (es) 2015-03-23
JP6050328B2 (ja) 2016-12-21
TW201726167A (zh) 2017-08-01
EP2710034A1 (en) 2014-03-26
IL263728A (en) 2019-01-31
EA028574B1 (ru) 2017-12-29
MA35180B1 (fr) 2014-06-02
TW201834687A (zh) 2018-10-01
KR20140043388A (ko) 2014-04-09
NZ618012A (en) 2016-03-31
JP2019142961A (ja) 2019-08-29
CO6821893A2 (es) 2013-12-31
PH12017501368A1 (en) 2018-01-29
TWI601537B (zh) 2017-10-11
AU2018201504A1 (en) 2018-03-22
JP2014515036A (ja) 2014-06-26
US9555126B2 (en) 2017-01-31
CL2013003272A1 (es) 2014-08-01
NI201300119A (es) 2014-02-28
US20170196988A1 (en) 2017-07-13
JP2017081926A (ja) 2017-05-18
AU2012258254B2 (en) 2016-04-21
ZA201309400B (en) 2015-04-29
JP6181273B2 (ja) 2017-08-16
EP2524929A1 (en) 2012-11-21
CN103547596A (zh) 2014-01-29
US20140072587A1 (en) 2014-03-13
MX2013013455A (es) 2014-02-17
AR086412A1 (es) 2013-12-11
CN107007840A (zh) 2017-08-04
IL229380B (en) 2018-02-28
WO2012156455A1 (en) 2012-11-22
CA2835738A1 (en) 2012-11-22
TW201249460A (en) 2012-12-16
UY34077A (es) 2013-01-03
BR112013029330A2 (pt) 2016-11-29
SG194894A1 (en) 2013-12-30
JP2018021020A (ja) 2018-02-08

Similar Documents

Publication Publication Date Title
EA201391714A1 (ru) Применение иммуноконъюгированного с майтанзиноидом антитела против cd19 для лечения симптомов b-клеточных злокачественных новообразований
NZ702748A (en) Cd33 antibodies and use of same to treat cancer
JO3097B1 (ar) الأجسام المضادة c-Met
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
EA201400579A1 (ru) Антитела к il-36r
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
EA201171374A1 (ru) Антитела против cd100 и способы их применения
EA201171367A1 (ru) Винилиндазолильные соединения
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
EA201300978A1 (ru) Антитела к сеа
EA201201357A1 (ru) Антитела к cd40
EA201001372A1 (ru) Формы рифаксимина и их применение
EA201400178A1 (ru) Лечение рака молочной железы
EA201391342A1 (ru) Cd37-связывающие молекулы и их иммуноконъюгаты
UY34230A (es) Terapia de combinación para tumores malignos de células b cd19+ que comprende un inmunoconjugado maitansinoide anti-cd19 y rituximab
EA201200998A1 (ru) Способы лечения рака поджелудочной железы
CL2011000931A1 (es) Anticuerpo humanizado anti-alfa2 integrina; uso del anticuerpo antes mencionado para tratar cancer.
GB201109238D0 (en) Antibodies
EA201590522A1 (ru) Способы введения рифаксимина для снижения веса и лечения ожирения
EA202090716A1 (ru) Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований
TH153141A (th) การใช้แอนติ-cd19 เมย์แทนซินซิดอิมมูโนคอนจูเกตแอนติบอดีสำหรับการรักษาอาการมะเร็งบีเซลล์
TR201905240T4 (tr) LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.
TN2013000507A1 (en) Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer.
NZ622728A (en) Use of 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methylpropyl]amino-3,4-dihydro- 2h-1,5-benzoxathiepine for treating cancer and in particular for preventing and/or treating cancer metastases
UA104739C2 (en) c-MET ANTIBODIES

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU